+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gout Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (NSAIDs, Corticosteroids, Colchicine), By Disease Condition (Acute, Chronic), By Distribution Channel, By Region, And Segment Forecasts, 2023-2030

  • PDF Icon

    Report

  • 100 Pages
  • June 2023
  • Region: Global
  • Grand View Research
  • ID: 5846786
Description Jump to:
The global gout therapeutics market size is expected to reach USD 4.13 billion by 2030 and expand at a CAGR of 6.25% from 2023 to 2030, according to this report. The growth of the market is attributed to the global rise in disease burden, initiatives undertaken by government and private organizations to spread awareness among people, and the recent development of novel therapies in the space. Furthermore, the growing number of clinical pipeline drugs offers lucrative market growth opportunities.

The world is witnessing an increasing prevalence of gout, which is the key factor driving market growth. For instance, according to an Elsevier article, in 2021, Australia reported prevalence rates between 1.5% to 2.9% for gout. Similarly, in 2021, Canada and UK reported approximately 4% and 2.33% rise in disease cases respectively. High prevalence is further supported by the high geriatric population, improper diets such as consumption of alcohol and fructose, increasing sedentary lifestyle, and comorbidities like renal impairment, cardiovascular diseases, and diabetes.

The robust clinical trial pipeline and the anticipated launch of new therapeutics are expected to boost market growth over the forecast period. Presently, drug candidates like Jiangsu HengRui Medicine Co., Ltd.’s SHR4640 are in phase 3 clinical investigation for the treatment of gout. Similarly, in March 2023, Selecta Biosciences, Inc announced positive results for the Phase 3 DISSOLVE I & II placebo-controlled randomized clinical trials of SEL-212. SEL-212 is indicated for chronic refractory gout.

Key players are undertaking strategic initiatives such as collaborations, mergers and acquisitions, agreements, and financial investments, driving market growth. For instance, in June 2021, Horizon Therapeutics plc collaborated with Arrowhead Pharmaceuticals to develop RNAi therapeutic, a potential treatment for uncontrolled gout. In July 2022, the company received expanded FDA approval for Krystexxa for patients with uncontrolled gout. It is used in combination with immunotherapy and chemotherapy drug, methotrexate.

Additionally, in March 2023, Horizon organized a campaign, “Weed it G'out” for National Kidney Month. The campaign uses flowers and weeds to depict the correlation to the effect of uric acid on kidneys. The campaign aims to create awareness and urge people to take gout seriously and consult a specialist.

Gout Therapeutics Market Report Highlights

  • NSAIDs segment accounted for the largest share of the market in 2022 due to the high prescription rate, low cost, and strong presence in the market.
  • Based on disease condition, the acute condition segment held 65.77% of the total market share in 2022, owing to a high patient pool compared to the chronic condition
  • In 2022, retail pharmacy held the highest segment share in the space. However, online pharmacy is expected to be the fastest-growing segment over the forecast period
  • North America dominated the global market in 2022 owing to factors such as increased gout cases, high awareness among individuals for disease treatment, and better healthcare access in the region
  • Some key players in the space include GlaxoSmithKline plc; Takeda Pharmaceutical Company Ltd.; Regeneron Pharmaceuticals Inc; Novartis AG; AstraZeneca plc; Merck & Co. Inc.; Teijin Ltd.; and Horizon Pharma plc; Zydus Group and others

Table of Contents

Chapter 1 Methodology And Scope
1.1 Market Segmentation
1.1.1 Estimates And Forecast Timeline
1.2 Market Definitions
1.3 Research Methodology
1.4 Information Procurement
1.4.1 Purchased Database
1.4.2 Secondary Sources
1.4.3 Primary Research
1.4.4 Details Of Primary Research
1.5 Information Or Data Analysis
1.5.1 Data Analysis Models
1.6 Market Formulation & Validation
1.7 Model Details
1.7.1 Commodity Flow Analysis
1.7.1.1 Approach 1: Commodity Flow Approach
1.7.1.2 Approach 2: Country-Wise Market Estimation Using The Bottom-Up Approach
1.8 Regional Market: Cagr Calculation
1.9 Research Assumptions
1.10 List Of Secondary Sources
1.11 List Of Abbreviations
1.12 Objectives
1.12.1 Objective 1
1.12.2 Objective 2
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Drug Class And Disease Condition Segment Snapshot
2.3 Distribution Chanel Segment Snapshot
2.4 Competitive Landscape Snapshot
Chapter 3 Global Gout Therapeutics Market Variables, Trends, & Scope
3.1 Gout Therapeutics Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Penetration And Growth Prospect Mapping
3.3 Regulatory Framework
3.4 Market Driver Analysis
3.4.1 Rising Prevalence Of Gout
3.4.2 Advanced And New Therapies With Strong R&D Pipeline
3.4.3 Rising Awareness Among People
3.5 Market Restraint Analysis
3.5.1 Delayed Disease Diagnosis In Developing And Underdeveloped Countries
3.6 Porter’s Five Forces Analysis
3.7 Pipeline Analysis
Chapter 4 Gout Therapeutics Market - Segment Analysis, By Drug Class, 2018 - 2030 (USD Million)
4.1 Global Gout Therapeutics Market: Drug Class Movement Analysis
4.2. Nsaids
4.2.1. Nsaids Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.3. Corticosteroids
4.3.1 Corticosteroids Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4. Colchicine
4.4.1 Colchicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.5. Urate-Lowering Agents
4.5.1 Urate-Lowering Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.6. Others
4.6.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 5 Gout Therapeutics - Segment Analysis, By Disease Condition, 2018 - 2030 (USD Million)
5.1. Global Gout Therapeutics Market: Disease Condition Movement Analysis
5.2. Acute Gout
5.2.1. Acute Gout Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.3. Chronic Gout
5.3.1. Chronic Gout Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 6 Gout Therapeutics Market- Segment Analysis, By Distribution Channel, 2018 - 2030 (USD Million)
6.1. Global Gout Therapeutics Market: Distribution Channel Movement Analysis
6.2. Hospital Pharmacy
6.2.1. Hospital Pharmacy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3. Retail Pharmacy
6.3.1. Retail Pharmacy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4. Online Pharmacy
6.4.1. Online Pharmacy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 7 Gout Therapeutics Market: - Segment Analysis, By Region, 2018 - 2030 (USD Million)
7.1 Gout Therapeutics Market: Regional Movement Analysis
7.1.1 Definition & Scope
7.2 North America
7.2.1 North America, Swot Analysis
7.2.2 U.S.
7.2.2.1 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.2.2.2 Key Country Dynamics
7.2.2.3 Target Disease Prevalence
7.2.2.4 Competitive Scenario
7.2.2.5 Regulatory Framework
7.2.2.6 Reimbursement Scenario
7.2.3 Canada
7.2.3.1 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.2.3.2 Key Country Dynamics
7.2.3.3 Target Disease Prevalence
7.2.3.4 Competitive Scenario
7.2.3.5 Regulatory Framework
7.2.3.6 Reimbursement Scenario
7.3 Europe
7.3.1 Europe, Swot Analysis
7.3.2 Uk
7.3.2.1 Uk Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.2.2 Key Country Dynamics
7.3.2.3 Target Disease Prevalence
7.3.2.4 Competitive Scenario
7.3.2.5 Regulatory Framework
7.3.2.6 Reimbursement Scenario
7.3.3 Germany
7.3.3.1 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.3.2 Key Country Dynamics
7.3.3.3 Target Disease Prevalence
7.3.3.4 Competitive Scenario
7.3.3.5 Regulatory Framework
7.3.3.6 Reimbursement Scenario
7.3.4 France
7.3.4.1 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.4.2 Key Country Dynamics
7.3.4.3 Target Disease Prevalence
7.3.4.4 Competitive Scenario
7.3.4.5 Regulatory Framework
7.3.4.6 Reimbursement Scenario
7.3.5 Italy
7.3.5.1 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.5.2 Key Country Dynamics
7.3.5.3 Target Disease Prevalence
7.3.5.4 Competitive Scenario
7.3.5.5 Regulatory Framework
7.3.5.6 Reimbursement Scenario
7.3.6 Spain
7.3.6.1 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.6.2 Key Country Dynamics
7.3.6.3 Target Disease Prevalence
7.3.6.4 Competitive Scenario
7.3.6.5 Regulatory Framework
7.3.6.6 Reimbursement Scenario
7.3.7 Sweden
7.3.7.1 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.7.2 Key Country Dynamics
7.3.7.3 Target Disease Prevalence
7.3.7.4 Competitive Scenario
7.3.7.5 Regulatory Framework
7.3.7.6 Reimbursement Scenario
7.3.8 Denmark
7.3.8.1 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.8.2 Key Country Dynamics
7.3.8.3 Target Disease Prevalence
7.3.8.4 Competitive Scenario
7.3.8.5 Regulatory Framework
7.3.8.6 Reimbursement Scenario
7.3.9 Norway
7.3.9.1 Norway Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.9.2 Key Country Dynamics
7.3.9.3 Target Disease Prevalence
7.3.9.4 Competitive Scenario
7.3.9.5 Regulatory Framework
7.3.9.6 Reimbursement Scenario
7.4 Asia Pacific
7.4.1 Asia Pacific, Swot Analysis
7.4.2 India
7.4.2.1 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4.2.2 Key Country Dynamics
7.4.2.3 Target Disease Prevalence
7.4.2.4 Competitive Scenario
7.4.2.5 Regulatory Framework
7.4.2.6 Reimbursement Scenario
7.4.3 China
7.4.3.1 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4.3.2 Key Country Dynamics
7.4.3.3 Target Disease Prevalence
7.4.3.4 Competitive Scenario
7.4.3.5 Regulatory Framework
7.4.3.6 Reimbursement Scenario
7.4.4 Japan
7.4.4.1 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4.4.2 Key Country Dynamics
7.4.4.3 Target Disease Prevalence
7.4.4.4 Competitive Scenario
7.4.4.5 Regulatory Framework
7.4.4.6 Reimbursement Scenario
7.4.5 Australia
7.4.5.1 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4.5.2 Key Country Dynamics
7.4.5.3 Target Disease Prevalence
7.4.5.4 Competitive Scenario
7.4.5.5 Regulatory Framework
7.4.5.6 Reimbursement Scenario
7.4.6 South Korea
7.4.6.1 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4.6.2 Key Country Dynamics
7.4.6.3 Target Disease Prevalence
7.4.6.4 Competitive Scenario
7.4.6.5 Regulatory Framework
7.4.6.6 Reimbursement Scenario
7.4.7 Thailand
7.4.7.1 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4.7.2 Key Country Dynamics
7.4.7.3 Target Disease Prevalence
7.4.7.4 Competitive Scenario
7.4.7.5 Regulatory Framework
7.4.7.6 Reimbursement Scenario
7.5 Latin America
7.5.1 Latin America, Swot Analysis
7.5.2 Mexico
7.5.2.1 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.5.2.2 Key Country Dynamics
7.5.2.3 Target Disease Prevalence
7.5.2.4 Competitive Scenario
7.5.2.5 Regulatory Framework
7.5.2.6 Reimbursement Scenario
7.5.3 Brazil
7.5.3.1 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.5.3.2 Key Country Dynamics
7.5.3.3 Target Disease Prevalence
7.5.3.4 Competitive Scenario
7.5.3.5 Regulatory Framework
7.5.3.6 Reimbursement Scenario
7.5.4 Argentina
7.5.4.1 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.5.4.2 Key Country Dynamics
7.5.4.3 Target Disease Prevalence
7.5.4.4 Competitive Scenario
7.5.4.5 Regulatory Framework
7.5.4.6 Reimbursement Scenario
7.6 MEA
7.6.1 Middle East & Africa, Swot Analysis
7.6.2 South Africa
7.6.2.1 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.6.2.2 Key Country Dynamics
7.6.2.3 Target Disease Prevalence
7.6.2.4 Competitive Scenario
7.6.2.5 Regulatory Framework
7.6.2.6 Reimbursement Scenario
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.6.3.2 Key Country Dynamics
7.6.3.3 Target Disease Prevalence
7.6.3.4 Competitive Scenario
7.6.3.5 Regulatory Framework
7.6.3.6 Reimbursement Scenario
7.6.4 UAE
7.6.4.1 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.6.4.2 Key Country Dynamics
7.6.4.3 Target Disease Prevalence
7.6.4.4 Competitive Scenario
7.6.4.5 Regulatory Framework
7.6.4.6 Reimbursement Scenario
7.6.5 Kuwait
7.6.5.1 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.6.5.2 Key Country Dynamics
7.6.5.3 Target Disease Prevalence
7.6.5.4 Competitive Scenario
7.6.5.5 Regulatory Framework
7.6.5.6 Reimbursement Scenario
Chapter 8 Competitive Landscape
8.1 Public Companies
8.1.1 Company Market Position Analysis
8.1.2 Competitive Dashboard Analysis
8.1.3 Strategic Framework
8.2 Private Companies
8.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
8.2.2 Regional Network Map
8.3 Company Profiles
8.3.1 Takeda Pharmaceutical Company Ltd.
8.3.1.1 Company Overview
8.3.1.2 Financial Performance
8.3.1.3 Product Benchmarking
8.3.1.4 Strategic Initiatives
8.3.2 Novartis Ag
8.3.2.1 Company Overview
8.3.2.2 Financial Performance
8.3.2.3 Product Benchmarking
8.3.2.4 Strategic Initiatives
8.3.3 Regeneron Pharmaceuticals Inc.
8.3.3.1 Company Overview
8.3.3.2 Financial Performance
8.3.3.3 Product Benchmarking
8.3.3.4 Strategic Initiatives
8.3.4 Astrazeneca Plc
8.3.4.1 Company Overview
8.3.4.2 Financial Performance
8.3.4.3 Product Benchmarking
8.3.4.4 Strategic Initiatives
8.3.5 Horizon Therapeutics Plc
8.3.5.1 Company Overview
8.3.5.2 Financial Performance
8.3.5.3 Product Benchmarking
8.3.5.4 Strategic Initiatives
8.3.6 Merck & Co. Inc
8.3.6.1 Company Overview
8.3.6.2 Financial Performance
8.3.6.3 Product Benchmarking
8.3.6.4 Strategic Initiatives
8.3.7 Zydus Group
8.3.7.1 Company Overview
8.3.7.2 Financial Performance
8.3.7.3 Product Benchmarking
8.3.7.4 Strategic Initiatives
8.3.8 Teijin Ltd
8.3.8.1 Company Overview
8.3.8.2 Financial Performance
8.3.8.3 Product Benchmarking
8.3.8.4 Strategic Initiatives
8.3.9 Glaxosmithkline Plc
8.3.9.1 Company Overview
8.3.9.2 Financial Performance
8.3.9.3 Product Benchmarking
8.3.9.4 Strategic Initiatives
List of Tables
Table 1: List of Secondary Sources
Table 2: List of Abbreviation
Table 3: List of Parameters
Table 4: List of Distributors
Table 5: Global Gout Therapeutics Market, By Region, 2018-2030 (USD Million)
Table 6: Global Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 7: Global Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 8: Global Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 9: North America Gout Therapeutics Market, By Country, 2018-2030 (USD Million)
Table 10: North America Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 11: North America Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 12: North America Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 13: U.S. Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 14: U.S. Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 15: U.S. Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 16: Canada Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 17: Canada Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 18: Canada Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 19: Europe Gout Therapeutics Market, By Country, 2018-2030 (USD Million)
Table 20: Europe Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 21: Europe Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 22: Europe Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 23: Germany Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 24: Germany Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 25: Germany Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 26: UK Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 27: UK Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 28: UK Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 29: France Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 30: France Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 31: France Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 32: Italy Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 33: Italy Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 34: Italy Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 35: Spain Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 36: Spain Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 37: Spain Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 38: Denmark Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 39: Denmark Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 40: Denmark Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 41: Sweden Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 42: Sweden Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 43: Sweden Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 44: Norway Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 45: Norway Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 46: Norway Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 47: Asia Pacific Gout Therapeutics Market, By Country, 2018-2030 (USD Million)
Table 48: Asia Pacific Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 49: Asia Pacific Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 50: Asia Pacific Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 51: Japan Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 52: Japan Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 53: Japan Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 54: China Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 55: China Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 56: China Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 57: India Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 58: India Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 59: India Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 60: South Korea Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 61: South Korea Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 62: South Korea Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 63: Australia Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 64: Australia Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 65: Australia Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 66: Thailand Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 67: Thailand Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 68: Thailand Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 69: Latin America Gout Therapeutics Market, By Country, 2018-2030 (USD Million)
Table 70: Latin America Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 71: Latin America Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 72: Latin America Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 73: Brazil Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 74: Brazil Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 75: Brazil Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 76: Mexico Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 77: Mexico Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 78: Mexico Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 79: Argentina Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 80: Argentina Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 81: Argentina Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 82: Middle East & Africa Gout Therapeutics Market, By Country, 2018-2030 (USD Million)
Table 83: Middle East & Africa Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 84: Middle East & Africa Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 85: Middle East & Africa Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 86: Saudi Arabia Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 87: Saudi Arabia Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 88: Saudi Arabia Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 89: South Africa Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 90: South Africa Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 91: South Africa Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 92: UAE Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 93: UAE Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 94: UAE Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
Table 95: Kuwait Gout Therapeutics Market, By Drug Class, 2018-2030 (USD Million)
Table 96: Kuwait Gout Therapeutics Market, By Disease Condition, 2018-2030 (USD Million)
Table 97: Kuwait Gout Therapeutics Market, By Distribution Channel, 2018-2030 (USD Million)
List of Figures
Fig. 1: Market research process
Fig. 2: Information procurement
Fig. 3: Primary research pattern
Fig. 4: Market research approaches
Fig. 5: Value chain-based sizing & Forecasting
Fig. 6: QFD modeling for market share assessment
Fig. 7: Market summary
Fig. 8: Market trends & outlook
Fig. 9: Market segmentation & scope
Fig. 10: Market driver relevance analysis (Current & future impact)
Fig. 11: Market restraint relevance analysis (Current & future impact)
Fig. 12: Penetration & growth prospect mapping
Fig. 13: Gout therapeutics market - PESTLE analysis
Fig. 14: Porter’s Five Forces Analysis
Fig. 15: Gout therapeutics market outlook key takeaways
Fig. 16: Gout therapeutics market: Drug class movement analysis
Fig. 17: Global gout therapeutics market, by drug class, 2018-2030 (USD Million)
Fig. 18: Global gout therapeutics market, 2018-2030 (USD Million)
Fig. 19: Global NSAIDs market, 2018-2030 (USD Million)
Fig. 20: Global corticosteroids market, 2018-2030 (USD Million)
Fig. 21: Global colchicine market, 2018-2030 (USD Million)
Fig. 22: Global urate-lowering agents market, 2018-2030 (USD Million)
Fig. 23: Global gout therapeutics market: Disease condition movement analysis
Fig. 24: Global gout therapeutics market, by disease condition, 2018-2030 (USD Million)
Fig. 25: Global acute gout market, 2018-2030 (USD Million)
Fig. 26: Global chronic gout market, 2018-2030 (USD Million)
Fig. 27: Global gout therapeutics market: Distribution Channel movement analysis
Fig. 28: Global gout therapeutics market, by distribution channel, 2018-2030 (USD Million)
Fig. 29: Global retail pharmacy market, 2018-2030 (USD Million)
Fig. 30: Global hospital pharmacy market, 2018-2030 (USD Million)
Fig. 31: Global online pharmacy market, 2018-2030 (USD Million)
Fig. 32: Regional market: Key takeaways
Fig. 33: Gout therapeutics market regional outlook, 2018 & 2030
Fig. 34: North America gout therapeutics market, 2018-2030 (USD Million)
Fig. 35: U.S. gout therapeutics market, 2018-2030 (USD Million)
Fig. 36: Canada gout therapeutics market, 2018-2030 (USD Million)
Fig. 37: Europe gout therapeutics market, 2018-2030 (USD Million)
Fig. 38: Germany gout therapeutics market, 2018-2030 (USD Million)
Fig. 39: UK gout therapeutics market, 2018-2030 (USD Million)
Fig. 40: France gout therapeutics market, 2018-2030 (USD Million)
Fig. 41: Italy gout therapeutics market, 2018-2030 (USD Million)
Fig. 42: Spain gout therapeutics market, 2018-2030 (USD Million)
Fig. 43: Denmark gout therapeutics market, 2018-2030 (USD Million)
Fig. 44: Sweden gout therapeutics market, 2018-2030 (USD Million)
Fig. 45: Norway gout therapeutics market, 2018-2030 (USD Million
Fig. 46: Asia Pacific gout therapeutics market, 2018-2030 (USD Million)
Fig. 47: Japan gout therapeutics market, 2018-2030 (USD Million)
Fig. 48: China gout therapeutics market, 2018-2030 (USD Million)
Fig. 49: India gout therapeutics market, 2018-2030 (USD Million)
Fig. 50: South Korea gout therapeutics market, 2018-2030 (USD Million)
Fig. 51: Australia gout therapeutics market, 2018-2030 (USD Million
Fig. 52: Thailand gout therapeutics market, 2018-2030 (USD Million
Fig. 53: Latin America gout therapeutics market, 2018-2030 (USD Million)
Fig. 54: Brazil gout therapeutics market, 2018-2030 (USD Million)
Fig. 55: Mexico gout therapeutics market, 2018-2030 (USD Million)
Fig. 56: Argentina gout therapeutics market, 2018-2030 (USD Million)
Fig. 57: Middle East Africa gout therapeutics market, 2018-2030 (USD Million)
Fig. 58: South Africa gout therapeutics market, 2018-2030 (USD Million)
Fig. 59: Saudi Arabia gout therapeutics market, 2018-2030 (USD Million)
Fig. 60: UAE gout therapeutics market, 2018-2030 (USD Million)
Fig. 61: Kuwait gout therapeutics market, 2018-2030 (USD Million
Fig. 62: Strategy frameworks

Companies Mentioned

  • Takeda Pharmaceutical Company Ltd.
  • Novartis Ag
  • Regeneron Pharmaceuticals Inc.
  • Astrazeneca Plc
  • Horizon Therapeutics Plc
  • Merck & Co. Inc
  • Zydus Group
  • Teijin Ltd
  • Glaxosmithkline Plc

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedJune 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 2.49 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.13 Billion
Compound Annual Growth Rate6.2%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Gout Therapeutics Market by Drug Class, Treatment, Route of Administration, Application - Global Forecast 2025-2030 - Product Image

Gout Therapeutics Market by Drug Class, Treatment, Route of Administration, Application - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Gout Therapeutics Global Market Report 2024 - Product Image

Gout Therapeutics Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Gout Therapeutics - Global Strategic Business Report - Product Image

Gout Therapeutics - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Acute Gout Flare - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Acute Gout Flare - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Gout Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Gout Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.